全球吸入麻醉劑市場 - 成長,趨勢,預測(2017年∼2022年)

Inhalation Anesthetics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 114 Pages | 商品交期: 2-3個工作天內



  • 全貌
  • 簡介
  • 目錄




第1章 簡介

  • 調查的成果
  • 市場定義
  • 調查對象期間與預測
  • 一般調查的前提條件
  • 報告概要

第2章 調查方法

  • 簡介
  • 分析方法
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論提綱
    • 市場工程&計量經濟學模式

第3章 摘要整理

第4章 主要推論

第5章 市場概要與產業趨勢

  • 市場概況
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 慢性疾病的發病率高的老年人口的增加
    • 緊急治療需要的案例增加
    • 對住院日數減少的需求高漲
    • 由於醫療服務獲取提高使手術數量增加
  • 市場阻礙因素
    • 幾乎全部的鹵素化劑的一般競爭
    • 最近的專利有效期限
  • 市場機會
  • 主要課題
    • 市場進入的高障礙

第7章 全球吸入麻醉劑市場:市場區隔

  • 各類型
    • 一氧化二氮(笑氣氣體)
    • 鹵素化劑

第8章 全球吸入麻醉劑市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(CGG)
    • 南非
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A分析
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • Baxter
  • Abbvie
  • Piramal Healthcare
  • Lunan Pharmaceuticals
  • 其他企業

第11章 分析師的投資機會預測

第12章 市場未來展望

Product Code: 46746

The inhalation anesthetics market is expected to register a CAGR of 3.7% during the forecast period. The market is expected to grow due to the increase in the number of surgeries being performed, globally. For instance, according to the annual estimates of Sedana Medical, there were about 4.5-7.5 million people ventilated and sedated worldwide in 2017. Furthermore, a rise in population pool, an increase in the number of the geriatric population prone to chronic diseases, growing demand for a lesser duration of hospitalization, and increasing accessibility to health services are some of the other factors responsible for the growth of the inhalation anesthetics market.

Inhalation anesthetics are also majorly used for accident care, where the intravenous route of administration is not an easy task in ambulatory settings. In emergency labors, rapid sequence induction of general anesthesia is performed with intubation of the trachea. Therefore, the increasing number of emergency cases all over the world is driving the inhalation anesthetics market.

As per the UN reports, the global population aged 60 years or over numbered 962 million in 2017, more than twice as large as in 1980, when there were 382 million older people worldwide. The number of older people is expected to double by 2050, projected to reach nearly 2.1 billion. However, side effects associated with the inhalation anesthetics, the lower adoption rate in case of inhaled anesthetics in certain surgical procedures, generic competition for almost all of the halogenated agents, and recent patent expiries are restraining the inhalation anesthetics market.

Key Market Trends

Sevoflurane Holds the Major Share in the Inhalation Anesthetics Market

Sevoflurane is the most widely used inhalational anesthetic, owing to its therapeutic advantages and low cost. Sevoflurane is an ether inhalation anesthetic agent with low pungency, a non-irritant odor, and a low blood, gas partition coefficient. It is found to be ideal for asthma patients or people with sensitized air passages. The drug has captured a major portion of the market, and it is expected to retain its position in the future as well.

The product is also marketed under the following names, Sojourn, Ultane, and Ultane PEN, in the United States, with Ultane being the most popular among all age groups. AbbVie is a key player of the market studied, and it sells Sevoflurane (sold under the trademarks Ultane and Sevorane) worldwide for human use.

Asia-Pacific is Expected to be the Fastest Growing Market

Asia-Pacific is expected to expand at the fastest CAGR over the forecast period. The key factors contributing to its rapid growth include increasing population, public and private healthcare expenditure, availability of healthcare insurance for masses, and incidence of chronic diseases. Asia-Pacific is anticipated to have a significant growth due to the presence of high unmet needs, an increase in health awareness, a large population base, and an increase in the number of surgeries. Moreover, propelling medical tourism due to the availability of cost-efficient and advanced healthcare treatment options, compared to the other geographical regions, and increasing adoption of novel technologies are bolstering the growth of the inhalational anesthetics market in Asia-Pacific.

North America also witnessed a rapid increase in the number of diseases, such as obesity, cardiovascular disease, and different types of cancers, which contributed to the growth of the inhalation anesthetics market in the region.

Competitive Landscape

Market players in the inhalation anesthetics market are focusing on the expansion of their product portfolios by adopting inorganic growth strategies, such as acquisitions, mergers, and partnerships. Only a few companies are coming forward with innovative technologies and new product launches. For example, in January 2019, Sandoz, a Novartis division, launched Desflurane Liquid for Inhalation, the first generic of Suprane, in the United States, as an inhalation agent for induction and maintenance of anesthesia for inpatient and outpatient surgery in adults, and for the maintenance of anesthesia for inpatient and outpatient surgery in pediatric patients.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Geriatric Population Prone to Chronic Diseases
    • 4.2.2 Increasing Number of Emergency Cases and Surgical Interventions
    • 4.2.3 Growing Demand for Lesser Duration in Hospitalization
    • 4.2.4 Increasing Accessibility to Health Services and Surgeries
  • 4.3 Market Restraints
    • 4.3.1 Generic Competition for Almost All Halogenated Agents
    • 4.3.2 Side-effects of Inhaler Anesthesia Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 Type
    • 5.1.1 Desflurane
    • 5.1.2 Sevoflurane
    • 5.1.3 Isoflurane
    • 5.1.4 Other Types
  • 5.2 End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Merck KGaA
    • 6.1.3 Baxter International Inc.
    • 6.1.4 Fresenius Kabi AG
    • 6.1.5 Halocarbon Products Corporation
    • 6.1.6 Hikma Pharmaceuticals PLC
    • 6.1.7 Jiangsu Hengrui Medicine Co. Ltd
    • 6.1.8 Lunan Pharmaceutical Group Co. Ltd
    • 6.1.9 Piramal Enterprises Limited
    • 6.1.10 Troikaa Pharmaceuticals Ltd